Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 138

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 138
---
 June 30, 2025. Our loss from operations for the six months ended June 30, 2024 and 2025 was $22.8 million and $3.9
million, respectively. Our business model has demonstrated improving operational leverage, which has enabled us to reach, on a non-GAAP income from operations basis, positive operating income after adjusting for stock-based compensation expense for
the six months ended June 30, 2025. During this period, we generated revenue of $125.5 million, representing 82% year-over-year revenue growth as compared to the six month ended June 30, 2024, with a gross margin of 65%. This translated to a
non-GAAP net operating income of $1.2 million for the six months ended June 30, 2025 compared to a non-GAAP net operating loss of $18.9 million for the six months ended June 30, 2024, which represented an improvement of approximately $20.1 million.

89

Since our founding, we have developed and commercially launched multiple products and achieved a number of significant
milestones as depicted in the chart below.

Key Corporate & Commercialization Milestones CORPORATE Company founded 2016 First shared lab space (half bench) 2017 2018 $15M Series A closed 2019 2020 PRENATAL NIH grant received for the first single-gene NIPT clinical study UNITY Fetal Risk Screen launched First single-gene NIPT validation study published in Nature Scientific Reports UNITY Aneuploidy Screen and Fetal RhD NIPT launched ACOG guidelines changed to recommend NIPT for all pregnant women $55M Series B closed 2021 First dedicated lab facility opened in Menlo Park (36,000 sqft) $125M Series C closed 2022 Lab facility expanded to Union City (+90,000 sqft) 2023 $130M Series D closed 500th employee hired 2024 2025 UNITY Fetal Antigen NIPT for alloimmunized pregnant patients launched Clinical outcomes data for UNITY Fetal Risk Screen published, demonstrating exceptional accuracy in general pregnancy population Global partnership with J&J Phase 3 clinical trial announced ACOG practice advisory changed, citing publications on UNITY Fetal RhD NIPT and Fetal Antigen NIPT 1,000,000th clinical test performed UNITY Fetal Risk Screen expanded to 14-gene conditions ONCOLOGY Northstar Select and Response launched for clinical use